To disseminate the findings generated in VALUE-Dx by using various forms of communication and educational activities and publications at all levels of stakeholder platforms to promote their uptake and implementation in daily clinical practice and policy
To develop innovative, effective ways to disseminate information for creating awareness of optimal diagnosis and prognosis of CA-ARTI to prevent unnecessary prescription and use of antibiotics, to improve coverage with antibiotics, and thus limit antibiotic resistance and associated health and socioeconomic impacts
To develop and to tailor materials to support the adoption of CA-ARTI-Dx in European community care settings
https://value-dx.eu/wp-content/uploads/2020/11/ispo.png7201280Tina Hoflandhttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngTina Hofland2020-11-17 14:29:442020-11-18 08:33:48VALUE-Dx at Virtual ISPOR Europe 2020
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2020-09-01 12:27:162020-11-18 08:34:25Webinar with the Expert Advisory Panel on September 30
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Tina Hoflandhttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngTina Hofland2020-06-26 11:31:312020-09-21 13:30:39Evaluating the clinical and cost-effectiveness of CA-ARTI diagnostics through PRUDENCE trial
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.